Public Health Emergency of International Concern (PHEIC)
Situation report – 194
Coronavirus disease 2019 (COVID-19)
1 August 2020
Confirmed cases :: 17 396 943 [week ago: 15 581 009]
Confirmed deaths :: 675 060 [week ago: 635 173]
COVID-19 Vaccines – Access/Procurement/ Supply
92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC
:: Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations
:: The Gavi COVAX AMC forms part of the COVAX Facility, a mechanism hosted by Gavi, the Vaccine Alliance, designed to guarantee rapid, fair and equitable access to COVID-19 vaccines for every country in the world, rich and poor
:: Dr Ngozi Okonjo-Iweala: “We are facing the most severe contraction of the economy since World War Two, and this crisis will have a terrible impact on the poorest and emerging economies.”
Geneva, 31 July 2020 – A total of 92 low- and middle-income countries and economies will be able to access COVID-19 vaccines through Gavi’s COVAX Advance Market Commitment (AMC), the Gavi Board agreed yesterday. The Board also agreed that the Gavi secretariat will host and administer the COVAX Facility, the umbrella mechanism to which 78 countries have already submitted written expressions of interest.
“We are facing the most severe contraction of the economy since World War Two, and this crisis will have a terrible impact on the poorest and emerging economies,” said Dr Ngozi Okonjo-Iweala, Chair of the Gavi Board. “These countries will have limited resources to access future COVID-19 vaccines: it is our duty to support them. Without this support the majority of the world’s population will continue to suffer from this disease even after we’ve developed a tool to tackle it. We now can stop this from happening.”
The 92 low- and middle-income countries and economies approved by the Gavi Board will be able to access vaccines through the COVAX AMC, which will also cover at least part of the cost. The COVAX AMC launched the 4th of June at the Global Vaccine Summit draws from the lessons of the successful Pneumococcal AMC. It forms part of the COVAX Facility, a mechanism designed to guarantee rapid, fair and equitable access to COVID-19 vaccines worldwide. COVAX will enable countries to have access to the world’s largest and most diverse COVID-19 vaccine portfolio. This means that, even if separate bilateral deals with vaccine manufacturers exist, through the Facility countries stand a far better chance of getting access to the vaccine or vaccines that prove to be most effective.
The high- and middle-income economies that have already submitted expressions of interest in the COVAX Facility will need now to enter into a legally binding agreement to purchase doses through the Facility. This commitment will need to be confirmed in the next month by making upfront financial contributions, enabling the Facility to enter into manufacturer agreements for future vaccine supply.
“We now have the framework in place to ensure that every economy, particularly the poorest nations, don’t get left behind in the race for a COVID-19 vaccine,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “This disease has spread at lightning speed across the globe, which means nobody is safe until everybody is safe. That’s why we now need support and vital funding to ensure that, once a safe, effective vaccine is ready, we can work on protecting the world and not just the lucky few. Gavi will work with governments, international organisations, manufacturers and civil society organisations to ensure doses get to those who need them.”